{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T15:22:58Z","timestamp":1789053778217,"version":"build-2803163510"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T00:00:00Z","timestamp":1752105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T00:00:00Z","timestamp":1752105600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Sanofi"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Evaluating the persistence of antibody titers produced by quadrivalent meningococcal vaccines is crucial for determining the optimal timing for primary and booster doses. Using 3 \u2212\u20097-year persistence data after a single priming dose of MenACYW-TT to fit a statistical model of antibody decay over time (10 years), this analysis modeled long-term antibody persistence for this vaccine in toddlers (12\u201323 months), adolescents\/young adults (13\u201326 years), and older adults (\u2265\u200956 years), comparing it with other vaccines (MCV4-TT, MenACWY-CRM, MPSV4).  The statistical model is based on a Bayesian approach and it accounts for vaccine- and age group-specific antibody decline, missing data, assay errors, and antibody boosting from breakthrough infections. At 10 years post-vaccination, it predicted comparable or higher seroprotective immunopersistence for MenACYW-TT (titers\u2009\u2265\u20091:8 with hSBA) versus (1) MCV4-TT in toddlers (77% [95% CI 70\u201384] vs. 17% [6\u201331] for serogroup C, 67% [59\u201374] vs. 36% [20\u201353] for serogroup W); (2) MenACWY-CRM in adolescents\/young adults (63% [55\u201371] vs. 40% [32\u201348] for serogroup C, 67% [59\u201374] vs. 57% [47\u201367] for serogroup W); and (3) MPSV4 in older adults (31% [23\u201339] vs. 22% [14\u201329] for serogroup C, 38% [31\u201346] vs. 20% [14\u201327] for serogroup W).  In conclusion, our analysis indicated similar or higher immune persistence at 10 years for MenACYW-TT compared with other quadrivalent meningococcal vaccines, particularly for serogroups C and W.<\/jats:p>","DOI":"10.1038\/s41598-025-08112-0","type":"journal-article","created":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T20:29:38Z","timestamp":1752179378000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Modeling antibody persistence after MenACYW-TT vaccination and comparative analysis with other quadrivalent meningococcal vaccines"],"prefix":"10.1038","volume":"15","author":[{"given":"Laurent","family":"Coudeville","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Bertrand-Gerentes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line","family":"Zocchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edith","family":"Langevin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siham","family":"Bchir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Coste","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Oster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,10]]},"reference":[{"key":"8112_CR1","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1186\/s12889-022-12795-9","volume":"22","author":"S Guedes","year":"2022","unstructured":"Guedes, S., Bertrand-Gerentes, I., Evans, K., Coste, F. & Oster, P. Invasive meningococcal disease in older adults in North America and Europe: is this the time for action? A review of the literature. BMC Public Health 22, 380. https:\/\/doi.org\/10.1186\/s12889-022-12795-9 (2022).","journal-title":"BMC Public Health"},{"key":"8112_CR2","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1056\/nejm200105033441807","volume":"344","author":"NE Rosenstein","year":"2001","unstructured":"Rosenstein, N. E., Perkins, B. A., Stephens, D. S., Popovic, T. & Hughes, J. M. Meningococcal disease. N. Engl. J. Med. 344, 1378\u20131388. https:\/\/doi.org\/10.1056\/nejm200105033441807 (2001).","journal-title":"N. Engl. J. Med."},{"key":"8112_CR3","unstructured":"Centers for Disease Control and Prevention. Clinical Overview of Meningococcal Disease, https:\/\/www.cdc.gov\/meningococcal\/hcp\/clinical\/index.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fmeningococcal%2Fclinical-info.html (2024)."},{"key":"8112_CR4","unstructured":"Centers for Disease Control and Prevention. Enhanced Meningococcal Disease Surveillance Report, 2022: Confirmed and Probable Cases Reported to the National Notifiable Diseases Surveillance System, https:\/\/www.cdc.gov\/meningococcal\/downloads\/NCIRD-EMS-Report-2022-508.pdf (2024)."},{"key":"8112_CR5","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1080\/21645515.2018.1532248","volume":"15","author":"R Booy","year":"2019","unstructured":"Booy, R., Gentile, A., Nissen, M., Whelan, J. & Abitbol, V. Recent changes in the epidemiology of Neisseria meningitidis serogroup W across the world, current vaccination policy choices and possible future strategies. Hum. Vaccine Immunother. 15, 470\u2013480. https:\/\/doi.org\/10.1080\/21645515.2018.1532248 (2019).","journal-title":"Hum. Vaccine Immunother."},{"key":"8112_CR6","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.1016\/j.vaccine.2017.03.007","volume":"35","author":"R Whittaker","year":"2017","unstructured":"Whittaker, R. et al. The epidemiology of invasive meningococcal disease in EU\/EEA countries, 2004\u20132014. Vaccine 35, 2034\u20132041. https:\/\/doi.org\/10.1016\/j.vaccine.2017.03.007 (2017).","journal-title":"Vaccine"},{"key":"8112_CR7","unstructured":"World Health Organisation. Immunization, Vaccines and Biologicals, https:\/\/www.who.int\/teams\/immunization-vaccines-and-biologicals\/diseases\/meningitis (2024)."},{"key":"8112_CR8","unstructured":"World Health Organisation. WHO Position Papers on Meningococcal Vaccines, https:\/\/www.who.int\/teams\/immunization-vaccines-and-biologicals\/policies\/position-papers\/meningococcal-vaccines (2015)."},{"key":"8112_CR9","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.3201\/eid2307.170236","volume":"23","author":"H Campbell","year":"2017","unstructured":"Campbell, H. et al. Emergency meningococcal ACWY vaccination program for teenagers to control group w meningococcal disease, England, 2015\u20132016. Emerg. Infect. Dis. 23, 1184\u20131187. https:\/\/doi.org\/10.3201\/eid2307.170236 (2017).","journal-title":"Emerg. Infect. Dis."},{"key":"8112_CR10","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1001\/jamapediatrics.2020.1990","volume":"174","author":"S Mbaeyi","year":"2020","unstructured":"Mbaeyi, S. et al. Incidence of meningococcal disease before and after implementation of quadrivalent meningococcal conjugate vaccine in the United States. JAMA Pediatr. 174, 843\u2013851. https:\/\/doi.org\/10.1001\/jamapediatrics.2020.1990 (2020).","journal-title":"JAMA Pediatr."},{"key":"8112_CR11","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1093\/cid\/ciab791","volume":"74","author":"M Ohm","year":"2022","unstructured":"Ohm, M. et al. Vaccine impact and effectiveness of meningococcal serogroup ACWY conjugate vaccine implementation in the Netherlands: A nationwide surveillance study. Clin. Infect. Dis. 74, 2173\u20132180. https:\/\/doi.org\/10.1093\/cid\/ciab791 (2022).","journal-title":"Clin. Infect. Dis."},{"key":"8112_CR12","first-page":"1","volume":"62","author":"AC Cohn","year":"2013","unstructured":"Cohn, A. C. et al. Prevention and control of meningococcal disease: Recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm. Rep. 62, 1\u201328 (2013).","journal-title":"MMWR Recomm. Rep."},{"key":"8112_CR13","unstructured":"European Centre for Disease Prevention and Control. Meningococcal Disease: Recommended Vaccinations, https:\/\/vaccine-schedule.ecdc.europa.eu\/Scheduler\/ByDisease?SelectedDiseaseId=48&SelectedCountryIdByDisease=-1 (2024)."},{"key":"8112_CR14","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1080\/14760584.2018.1521280","volume":"17","author":"P Keshavan","year":"2018","unstructured":"Keshavan, P., Pellegrini, M., Vadivelu-Pechai, K. & Nissen, M. An update of clinical experience with the quadrivalent meningococcal ACWY-CRM conjugate vaccine. Expert Rev. Vaccines 17, 865\u2013880. https:\/\/doi.org\/10.1080\/14760584.2018.1521280 (2018).","journal-title":"Expert Rev. Vaccines"},{"key":"8112_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms8101521","author":"M Pizza","year":"2020","unstructured":"Pizza, M., Bekkat-Berkani, R. & Rappuoli, R. Vaccines against meningococcal diseases. Microorganisms https:\/\/doi.org\/10.3390\/microorganisms8101521 (2020).","journal-title":"Microorganisms"},{"key":"8112_CR16","unstructured":"Food and Drug Administration. MENVEO\u00ae: Prescribing Information, https:\/\/www.fda.gov\/media\/78514\/download (2022)."},{"key":"8112_CR17","unstructured":"European Medicines Agency. MENVEO\u00ae: Prescribing Information, https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/menveo-epar-product-information_en.pdf (2023)."},{"key":"8112_CR18","unstructured":"Food and Drug Administration. MENACTRA\u00ae: Prescribing Information, https:\/\/www.fda.gov\/files\/vaccines,%20blood%20&%20biologics\/published\/Package-Insert---Menactra.pdf (2018)."},{"key":"8112_CR19","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1080\/21645515.2016.1143157","volume":"12","author":"A Assaf-Casals","year":"2016","unstructured":"Assaf-Casals, A. & Dbaibo, G. Meningococcal quadrivalent tetanus toxoid conjugate vaccine (MenACWY-TT, Nimenrix\u2122): A review of its immunogenicity, safety, co-administration, and antibody persistence. Hum. Vaccine Immunother. 12, 1825\u20131837. https:\/\/doi.org\/10.1080\/21645515.2016.1143157 (2016).","journal-title":"Hum. Vaccine Immunother."},{"key":"8112_CR20","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.2165\/11209580-000000000-00000","volume":"72","author":"JD Croxtall","year":"2012","unstructured":"Croxtall, J. D. & Dhillon, S. Meningococcal quadrivalent (serogroups A, C, W135 and Y) tetanus toxoid conjugate vaccine (Nimenrix\u2122). Drugs 72, 2407\u20132430. https:\/\/doi.org\/10.2165\/11209580-000000000-00000 (2012).","journal-title":"Drugs"},{"key":"8112_CR21","unstructured":"European Medicines Agency. Nimenrix\u00ae: Prescribing Information, https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/nimenrix-epar-product-information_en.pdf (2024)."},{"key":"8112_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/21645515.2021.1902701","volume":"18","author":"FM Piazza","year":"2022","unstructured":"Piazza, F. M. et al. Immunogenicity and safety of an investigational quadrivalent meningococcal conjugate vaccine administered as a booster dose in children vaccinated against meningococcal disease 3 years earlier as toddlers: A phase III, open-label, multi-center study. Hum. Vaccine Immunother. 18, 1\u201310. https:\/\/doi.org\/10.1080\/21645515.2021.1902701 (2022).","journal-title":"Hum. Vaccine Immunother."},{"key":"8112_CR23","unstructured":"Food and Drug Administration. MenQuadfi\u00ae, https:\/\/www.fda.gov\/vaccines-blood-biologics\/menquadfi (2023)."},{"key":"8112_CR24","unstructured":"European Medicines Agency. MenQuadfi\u00ae: Prescribing Information, https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/menquadfi-epar-product-information_en.pdf (2024)."},{"key":"8112_CR25","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1080\/21645515.2020.1733869","volume":"16","author":"T Vesikari","year":"2020","unstructured":"Vesikari, T. et al. Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in healthy toddlers: A phase II randomized study. Hum. Vaccine Immunother. 16, 1306\u20131312. https:\/\/doi.org\/10.1080\/21645515.2020.1733869 (2020).","journal-title":"Hum. Vaccine Immunother."},{"key":"8112_CR26","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1038\/s41390-023-02478-5","volume":"94","author":"B Zambrano","year":"2023","unstructured":"Zambrano, B. et al. Quadrivalent meningococcal tetanus toxoid-conjugate booster vaccination in adolescents and adults: Phase III randomized study. Pediatr. Res. 94, 1035\u20131043. https:\/\/doi.org\/10.1038\/s41390-023-02478-5 (2023).","journal-title":"Pediatr. Res."},{"key":"8112_CR27","doi-asserted-by":"publisher","first-page":"3560","DOI":"10.1016\/j.vaccine.2020.03.017","volume":"38","author":"LJ Chang","year":"2020","unstructured":"Chang, L. J. et al. A phase II, randomized, immunogenicity and safety study of a quadrivalent meningococcal conjugate vaccine, MenACYW-TT, in healthy adolescents in the United States. Vaccine 38, 3560\u20133569. https:\/\/doi.org\/10.1016\/j.vaccine.2020.03.017 (2020).","journal-title":"Vaccine"},{"key":"8112_CR28","doi-asserted-by":"publisher","first-page":"5194","DOI":"10.1016\/j.vaccine.2020.06.013","volume":"38","author":"MS Dhingra","year":"2020","unstructured":"Dhingra, M. S. et al. Immunogenicity, safety and inter-lot consistency of a meningococcal conjugate vaccine (MenACYW-TT) in adolescents and adults: A phase III randomized study. Vaccine 38, 5194\u20135201. https:\/\/doi.org\/10.1016\/j.vaccine.2020.06.013 (2020).","journal-title":"Vaccine"},{"key":"8112_CR29","doi-asserted-by":"publisher","first-page":"2160600","DOI":"10.1080\/21645515.2022.2160600","volume":"19","author":"CA Robertson","year":"2023","unstructured":"Robertson, C. A., Jacqmein, J., Selmani, A., Galarza, K. & Oster, P. Immunogenicity and safety of a quadrivalent meningococcal conjugate vaccine (MenACYW-TT) administered as a booster to adults aged \u226559 years: A phase III randomized study. Hum. Vaccine Immunother. 19, 2160600. https:\/\/doi.org\/10.1080\/21645515.2022.2160600 (2023).","journal-title":"Hum. Vaccine Immunother."},{"key":"8112_CR30","doi-asserted-by":"publisher","first-page":"2426868","DOI":"10.1080\/21645515.2024.2426868","volume":"20","author":"CA Robertson","year":"2024","unstructured":"Robertson, C. A., Jacqmein, J., Selmani, A., Galarza, K. & Oster, P. Immune persistence and booster response of a quadrivalent meningococcal conjugate vaccine (MenACYW-TT) 5 years after primary vaccination of adults at \u226556 years of age. Hum. Vaccine Immunother. 20, 2426868. https:\/\/doi.org\/10.1080\/21645515.2024.2426868 (2024).","journal-title":"Hum. Vaccine Immunother."},{"key":"8112_CR31","unstructured":"Sanofi. Sanofi Pasteur statement on the discontinuation of Meningococcal polysaccharide vaccine, groups A, C, Y and W-135 combined., https:\/\/www.news.sanofi.us\/Sanofi-Pasteur-Statement-on-the-Discontinuation-of-Meningococcal-Polysaccharide-Vaccine-Groups-A-C-Y-and-W-135-Combined (2017)."},{"key":"8112_CR32","doi-asserted-by":"publisher","first-page":"4405","DOI":"10.1016\/j.vaccine.2020.04.067","volume":"38","author":"A Esteves-Jaramillo","year":"2020","unstructured":"Esteves-Jaramillo, A. et al. Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in \u226556-year-olds: A phase III randomized study. Vaccine 38, 4405\u20134411. https:\/\/doi.org\/10.1016\/j.vaccine.2020.04.067 (2020).","journal-title":"Vaccine"},{"key":"8112_CR33","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1080\/21645515.2020.1733868","volume":"16","author":"J Kirstein","year":"2020","unstructured":"Kirstein, J., Pina, M., Pan, J., Jordanov, E. & Dhingra, M. S. Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in adults 56 years of age and older: A phase II randomized study. Hum. Vaccine Immunother. 16, 1299\u20131305. https:\/\/doi.org\/10.1080\/21645515.2020.1733868 (2020).","journal-title":"Hum. Vaccine Immunother."},{"key":"8112_CR34","doi-asserted-by":"publisher","unstructured":"Martin\u00f3n-Torres, F. S., R; Ebert, R; R\u00e4met, M; Zocchetti, C; Syrkina, O; Bchir, S; Bertrand_Gerentes, I. Five-year immune persistence of a quadrivalent meningococcal conjugate vaccine (MenACYW-TT) and immunogenicity and safety of a booster dose in children. Infect Dis Ther. 14, 991\u20131010. https:\/\/doi.org\/10.1007\/s40121-025-01121-6 (2025)","DOI":"10.1007\/s40121-025-01121-6"},{"key":"8112_CR35","doi-asserted-by":"publisher","first-page":"e50","DOI":"10.1017\/s0950268821000261","volume":"149","author":"D van der Vliet","year":"2021","unstructured":"van der Vliet, D. et al. Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) vs. a licensed quadrivalent meningococcal tetanus toxoid-conjugate vaccine in meningococcal vaccine-na\u00efve and meningococcal C conjugate vaccine-primed toddlers: A phase III randomised study. Epidemiol. Infect. 149, e50. https:\/\/doi.org\/10.1017\/s0950268821000261 (2021).","journal-title":"Epidemiol. Infect."},{"key":"8112_CR36","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1007\/s40121-023-00864-4","volume":"12","author":"D Neveu","year":"2023","unstructured":"Neveu, D. et al. Structured benefit-risk assessment of a new quadrivalent meningococcal conjugate vaccine (MenACYW-TT) in individuals ages 12 months and older. Infect. Dis. Ther. 12, 2367\u20132386. https:\/\/doi.org\/10.1007\/s40121-023-00864-4 (2023).","journal-title":"Infect. Dis. Ther."},{"issue":"Suppl 2","key":"8112_CR37","doi-asserted-by":"publisher","first-page":"B117","DOI":"10.1016\/j.vaccine.2009.04.066","volume":"27","author":"DM Granoff","year":"2009","unstructured":"Granoff, D. M. Relative importance of complement-mediated bactericidal and opsonic activity for protection against meningococcal disease. Vaccine 27(Suppl 2), B117-125. https:\/\/doi.org\/10.1016\/j.vaccine.2009.04.066 (2009).","journal-title":"Vaccine"},{"key":"8112_CR38","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1080\/14760584.2021.1940144","volume":"21","author":"J Findlow","year":"2022","unstructured":"Findlow, J., Lucidarme, J., Taha, M. K., Burman, C. & Balmer, P. Correlates of protection for meningococcal surface protein vaccines: lessons from the past. Expert Rev. Vaccines 21, 739\u2013751. https:\/\/doi.org\/10.1080\/14760584.2021.1940144 (2022).","journal-title":"Expert Rev. Vaccines"},{"issue":"8","key":"8112_CR39","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1007\/s40121-024-01009-x","volume":"13","author":"I Bertrand-Gerentes","year":"2024","unstructured":"Bertrand-Gerentes, I. et al. Immunogenicity and safety of a booster dose and immune persistence of quadrivalent meningococcal conjugate vaccine (MenACYW-TT) in children primed as toddlers 5 years earlier. Infect. Dis. Ther. 13(8), 1835\u20131859 (2024).","journal-title":"Infect. Dis. Ther."},{"key":"8112_CR40","first-page":"431","volume":"41","author":"RC Gupta","year":"1999","unstructured":"Gupta, R. C., Akman, O. & Lvin, S. A study of log-logistic model in survival analysis. Biomed. J. 41, 431\u2013443 (1999).","journal-title":"Biomed. J."},{"key":"8112_CR41","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1016\/j.jpeds.2014.02.025","volume":"164","author":"R Baxter","year":"2014","unstructured":"Baxter, R. et al. Antibody persistence and booster response of a quadrivalent meningococcal conjugate vaccine in adolescents. J. Pediatr. 164, 1409-1415.e1404. https:\/\/doi.org\/10.1016\/j.jpeds.2014.02.025 (2014).","journal-title":"J. Pediatr."},{"key":"8112_CR42","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1080\/21645515.2015.1058457","volume":"12","author":"T Vesikari","year":"2016","unstructured":"Vesikari, T., Forsten, A., Bianco, V., Van der Wielen, M. & Miller, J. M. Antibody persistence up to 5 years after vaccination of toddlers and children between 12 months and 10 years of age with a quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine. Hum. Vaccine Immunother. 12, 132\u2013139. https:\/\/doi.org\/10.1080\/21645515.2015.1058457 (2016).","journal-title":"Hum. Vaccine Immunother."},{"key":"8112_CR43","doi-asserted-by":"publisher","first-page":"2510","DOI":"10.1016\/j.vaccine.2012.02.005","volume":"30","author":"K Desai","year":"2012","unstructured":"Desai, K., Coudeville, L. & Bailleux, F. Modelling the long-term persistence of neutralizing antibody in adults after one dose of live attenuated Japanese encephalitis chimeric virus vaccine. Vaccine 30, 2510\u20132515. https:\/\/doi.org\/10.1016\/j.vaccine.2012.02.005 (2012).","journal-title":"Vaccine"},{"key":"8112_CR44","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1016\/j.vaccine.2019.12.049","volume":"38","author":"C Espul","year":"2020","unstructured":"Espul, C. et al. Statistical modeling alongside observational data predicts long-term immunogenicity of one dose and two doses of pediatric hepatitis A vaccine in the Mendoza province of Argentina. Vaccine 38, 1715\u20131722. https:\/\/doi.org\/10.1016\/j.vaccine.2019.12.049 (2020).","journal-title":"Vaccine"},{"key":"8112_CR45","unstructured":"Stan. RStan: the R interface to Stan. R package version 2.21.2., http:\/\/mc-stan.org\/ (2020)."},{"key":"8112_CR46","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1007\/s11222-016-9696-4","volume":"27","author":"A Vehtari","year":"2017","unstructured":"Vehtari, A., Gelman, A. & Gabry, J. Practical Bayesian model evaluation using leave-one-out cross-validation and WAIC. Stat. Comput. 27, 1413\u20131432. https:\/\/doi.org\/10.1007\/s11222-016-9696-4 (2017).","journal-title":"Stat. Comput."},{"key":"8112_CR47","doi-asserted-by":"publisher","first-page":"333","DOI":"10.2307\/3316081","volume":"29","author":"F Alqallaf","year":"2001","unstructured":"Alqallaf, F. & Gustafson, P. On cross-validation of Bayesian models. Can. J. Stat. 29, 333\u2013340 (2001).","journal-title":"Can. J. Stat."},{"key":"8112_CR48","unstructured":"World Health Organisation. WHO Immunological Basis for Immunization Series: Module 15: Meningococcal Disease, https:\/\/www.who.int\/publications\/i\/item\/9789240017481 (2020)."},{"key":"8112_CR49","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1080\/14760584.2024.2348609","volume":"23","author":"C Burman","year":"2024","unstructured":"Burman, C., Knuf, M., S\u00e1fadi, M. A. P. & Findlow, J. Antibody persistence and revaccination recommendations of MenACWY-TT: A review of clinical studies assessing antibody persistence up to 10 years after vaccination. Expert Rev. Vaccines 23, 614\u2013635. https:\/\/doi.org\/10.1080\/14760584.2024.2348609 (2024).","journal-title":"Expert Rev. Vaccines"},{"key":"8112_CR50","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1080\/21645515.2015.1136040","volume":"12","author":"R Baxter","year":"2016","unstructured":"Baxter, R., Keshavan, P., Welsch, J. A., Han, L. & Smolenov, I. Persistence of the immune response after MenACWY-CRM vaccination and response to a booster dose, in adolescents, children and infants. Hum. Vaccine Immunother. 12, 1300\u20131310. https:\/\/doi.org\/10.1080\/21645515.2015.1136040 (2016).","journal-title":"Hum. Vaccine Immunother."},{"key":"8112_CR51","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1001\/archpedi.159.10.907","volume":"159","author":"H Keyserling","year":"2005","unstructured":"Keyserling, H. et al. Safety, immunogenicity, and immune memory of a novel meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine (MCV-4) in healthy adolescents. Arch. Pediatr. Adolesc. Med. 159, 907\u2013913. https:\/\/doi.org\/10.1001\/archpedi.159.10.907 (2005).","journal-title":"Arch. Pediatr. Adolesc. Med."},{"key":"8112_CR52","doi-asserted-by":"publisher","first-page":"4097","DOI":"10.1016\/j.vaccine.2005.03.045","volume":"23","author":"A Larrauri","year":"2005","unstructured":"Larrauri, A., Cano, R., Garc\u00eda, M. & Mateo, S. Impact and effectiveness of meningococcal C conjugate vaccine following its introduction in Spain. Vaccine 23, 4097\u20134100. https:\/\/doi.org\/10.1016\/j.vaccine.2005.03.045 (2005).","journal-title":"Vaccine"},{"key":"8112_CR53","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1080\/21645515.2020.1746110","volume":"16","author":"T Vesikari","year":"2020","unstructured":"Vesikari, T. et al. Ten-year antibody persistence and booster response to MenACWY-TT Vaccine after primary vaccination at 1\u201310 years of age. Hum. Vaccin Immunother. 16, 1280\u20131291. https:\/\/doi.org\/10.1080\/21645515.2020.1746110 (2020).","journal-title":"Hum. Vaccin Immunother."},{"key":"8112_CR54","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1007\/s40265-017-0828-8","volume":"77","author":"S Dhillon","year":"2017","unstructured":"Dhillon, S. & Pace, D. Meningococcal quadrivalent tetanus toxoid conjugate vaccine (MenACWY-TT; Nimenrix(\u00ae)): A review. Drugs 77, 1881\u20131896. https:\/\/doi.org\/10.1007\/s40265-017-0828-8 (2017).","journal-title":"Drugs"},{"key":"8112_CR55","doi-asserted-by":"publisher","first-page":"881","DOI":"10.4161\/hv.6.11.12849","volume":"6","author":"CJ Gill","year":"2010","unstructured":"Gill, C. J., Baxter, R., Anemona, A., Ciavarro, G. & Dull, P. Persistence of immune responses after a single dose of novartis meningococcal serogroup A, C, W-135 and Y CRM-197 conjugate vaccine (Menveo\u00ae) or Menactra\u00ae among healthy adolescents. Hum Vaccin 6, 881\u2013887. https:\/\/doi.org\/10.4161\/hv.6.11.12849 (2010).","journal-title":"Hum Vaccin"},{"key":"8112_CR56","doi-asserted-by":"publisher","first-page":"4460","DOI":"10.1016\/j.vaccine.2019.06.076","volume":"37","author":"NP Klein","year":"2019","unstructured":"Klein, N. P. et al. Antibody persistence and booster response following MenACWY-CRM vaccination in children as assessed by two different assay methods. Vaccine 37, 4460\u20134467. https:\/\/doi.org\/10.1016\/j.vaccine.2019.06.076 (2019).","journal-title":"Vaccine"},{"key":"8112_CR57","unstructured":"World Health Organisation. Correlates of vaccine-induced protection: methods and implications, https:\/\/researchonline.lshtm.ac.uk\/id\/eprint\/2728969\/1\/Correlatesofvaccine-induced.pdf (2013)."},{"key":"8112_CR58","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms12040775","author":"E Quiros-Roldan","year":"2024","unstructured":"Quiros-Roldan, E., Sottini, A., Natali, P. G. & Imberti, L. The impact of immune system aging on infectious diseases. Microorganisms\u00a011, 775.\u00a0https:\/\/doi.org\/10.3390\/microorganisms12040775 (2024).","journal-title":"Microorganisms"},{"key":"8112_CR59","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1007\/s41999-024-00969-0","volume":"15","author":"C Weil-Olivier","year":"2024","unstructured":"Weil-Olivier, C. et al. Invasive meningococcal disease in older adults: current perspectives and call for action. Eur. Geriatr. Med. 15, 729\u2013741. https:\/\/doi.org\/10.1007\/s41999-024-00969-0 (2024).","journal-title":"Eur. Geriatr. Med."},{"key":"8112_CR60","unstructured":"Sant\u00e9 Publique France. https:\/\/www.santepubliquefrance.fr\/maladies-et-traumatismes\/maladies-a-prevention-vaccinale\/infections-invasives-a-meningocoque\/documents\/bulletin-national2\/infections-invasives-a-meningocoque-en-france-au-31-janvier-2025 (2025)."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-08112-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-08112-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-08112-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T04:50:32Z","timestamp":1757220632000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-08112-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,10]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["8112"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-08112-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,10]]},"assertion":[{"value":"18 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"LC, IB-G, CZ, EL, SB, FC and PO are employees of Sanofi and may hold shares and\/or stock options in the company.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was conducted in accordance with the protocol and consensus ethical principles derived from international guidelines including the Declaration of Helsinki, and the International Council for Harmonisation (ICH) guidelines for Good Clinical Practice (GCP), all applicable laws, rules, and regulations.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"24990"}}